<div id="readability-page-1"><div><p>Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of <strong>Acrivon Therapeutics, Inc.</strong> (NASDAQ:ACRV), it sends a favourable message to the company's shareholders.</p><p> Although we don't think shareholders should simply follow insider transactions,  we do think it is perfectly logical to keep tabs on what insiders are doing. </p> <p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p><h2> The Last 12 Months Of Insider Transactions At Acrivon Therapeutics </h2> <p> In the last twelve months, the biggest single purchase by an insider was when Co-Founder Peter Blume-Jensen bought US$82k worth of shares at a price of US$1.68 per share.    That means that an insider was happy to buy shares at above the current price of US$1.65.  While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future.  To us, it's very important to consider the price insiders pay for shares.   As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.     </p> <p> In the last twelve months Acrivon Therapeutics insiders were buying shares, but not selling.    You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below.  If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! </p><p><span> See our latest analysis for Acrivon Therapeutics </span></p><p> There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this <strong>free</strong> list of companies. (Hint: insiders have been buying them). </p> <h2> Insider Ownership </h2><p> Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders.  We usually like to see fairly high levels of insider ownership.   Insiders own 6.1% of Acrivon Therapeutics shares, worth about US$4.6m, according to our data.  We do generally prefer see higher levels of insider ownership.  </p><h2> So What Do The Acrivon Therapeutics Insider Transactions Indicate? </h2><p> It doesn't really mean much that no insider has traded Acrivon Therapeutics shares in the last quarter.    However, our analysis of transactions over the last year is heartening.   The transactions are fine but it'd be more encouraging if Acrivon Therapeutics insiders bought more shares in the company.      So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company.    For example, Acrivon Therapeutics has <strong>6 warning signs</strong> (and 3 which are concerning) we think you should know about.  </p><p> If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this <strong>free</strong> list of interesting companies, that have HIGH return on equity and low debt. </p><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p></div></div>

ACRV

SBIO

LABU

ARKG

<p>Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has seen multiple insiders buying shares, which is generally a positive sign for shareholders. The largest purchase was by Co-Founder Peter Blume-Jensen, who bought $82k worth at $1.68 per share, above the current price of $1.65. Insiders own 6.1% of the company, valued at approximately $4.6m. While insider transactions are encouraging, there are also 6 warning signs to consider regarding the company's risks.</p>

Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock